SCHEMBL21028026

SCHEMBL21028026

CS(=O)(=O)c1ccc(Cc2c3n(c4ccccc24)C(CC(=O)O)CCC3)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 9/20 0.46
PTGDR Q13258 11/20 0.41
TBXA2R P21731 8/20 0.41
CYP2C9 P11712 3/20 0.40
CYP3A4 P08684 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
HSD17B10 Q99714 1/20 0.40
FFAR1 O14842 2/20 0.39
PDE2A O00408 1/20 0.39
DRD2 P14416 1/20 0.37
GABRA1 P14867 1/20 0.37
ADRA1D P25100 1/20 0.37
SLC6A3 Q01959 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21028023 0.91 PTGDR2 (0.39) PTGDR2PTGDRALDH1A1HPGD
SCHEMBL21027975 0.87 PTGDR2 (0.44) PTGDR2PTGDRTBXA2RCYP2C9CYP3A4
SCHEMBL21028080 0.85 FFAR1 (0.39) PTGDR2PTGDRTBXA2RMEN1ALDH1A1
SCHEMBL21028002 0.83 PTGDR2 (0.42) PTGDR2PTGDRTBXA2RCYP2C9CYP3A4
SCHEMBL21028081 0.81 PTGDR2 (0.39) PTGDR2PTGDR
SCHEMBL21028288 0.79 PTGDR2 (0.52) PTGDR2PTGDRTBXA2RCYP2C9CYP3A4
SCHEMBL24141336 0.78 PER2 (0.39) PTGDR2PTGDR
SCHEMBL21028076 0.76 KDM4E (0.42) PTGDRTBXA2RMEN1ALDH1A1KMT2A
SCHEMBL21028287 0.71 PTGDR2 (0.41) PTGDR2PTGDRTBXA2RCYP2C9CYP3A4
SCHEMBL23422218 0.65 TP53 (0.61) PTGDR2MEN1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524958-B2 Tricyclic compound as CRTH2 inhibitor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-12-13 US disclosed
US-20210403466-A1 TRICYCLIC COMPUND AS CRTH2 INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2021-12-30 US disclosed
EP-3489235-A1 TRICYCLIC COMPOUND AS CRTH2 INHIBITOR Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2019-05-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210403466-A1 TRICYCLIC COMPUND AS CRTH2 INHIBITOR NR3C2, CRHR2, CRHR1 PTGDR2 152/4885PTGDR 412/4885TBXA2R 184/4885
US-11524958-B2 Tricyclic compound as CRTH2 inhibitor NR1H2, NR3C2, NR1H4 PTGDR2 313/4885PTGDR 550/4885TBXA2R 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.